Caris Life Sciences
Tracked across 2 events · 89 articles · First seen May 29, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
The The Schall Law Firm has announced an investigation into Caris Life Sciences for potential violations of securities laws. This follows Caris Life Sciences' Q1 financial results reported on May 12, 2026, which showed a…
Impact: Caris Life Sciences is under investigation for allegedly issuing false and/or misleading statements and failing to disclose pertinent information to investors, leading to a decline in its stock price and a cut in revenue guidance.
Jun 02, 2026 · 15 articles
Tech
Researchers have reported a significant breakthrough in treating advanced pancreatic cancer with an experimental pill called daraxonrasib, developed by Revolution Medicines. The daily pill nearly doubled the median survival time for patients whose metastatic cancer…
Impact: Caris Life Sciences' chief medical officer, George Sledge, provided expert commentary on the significance of Daraxonrasib's breakthrough in targeting the KRAS mutation.
May 29, 2026 · 74 articles
100
The Schall Law Firm announced investigation Caris Life SciencesSchall Law Investigates...
100
Pomerantz LLP investigating claims Caris Life SciencesSchall Law Investigates...
92
Caris Life Sciences reported Q1 resultsSchall Law Investigates...
85
Caris Life Sciences delayed FDA clearance United States — Food and Drug AdministrationSchall Law Investigates...
NEWSDESK
Track Caris Life Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard